To evaluate these predictions, our simulations should be compared with the efficacy of various β-blockers and GRK2 inhibitors, administered both separately and concurrently, for reducing mortality and heart failure symptoms particularly in early HF. The gene discussed is GRK2; the disease is heart failure.